Welltok adds four new digital programs, Atrium Health adopts Butterfly's handheld ultrasound and more digital health deals

Also: Intel, UPenn and others employ AI for brain tumor identification; DrChrono integrates EHRsynergy's documentation tool.
By Dave Muoio
04:16 pm
Share

Consumer health company Welltok announced today that it will be including remote condition management programs from four new digital health services as part of its Connect Partner program. These four offerings include a Type 2 diabetes reversal program from Virta Health, a gut health program from Vivante Health, a telemedicine treatment program for addiction from Workit Health and a dietitian-guided program for multiple conditions from Nutrimedy.

“With people living in a more virtual world, we are seeing a shift in how people are managing conditions,” Bob Fabbio, CEO of Welltok, said in a statement. “Our partners are delivering much needed support to help people manage a healthy lifestyle, diabetes, addiction and other conditions at home. We are proud to be making their innovative solutions conveniently available through our platform and connecting them to the people who need them most.”


Charlotte, North Carolina-based health system Atrium Health announced yesterday that it will be the first to bring Butterfly's point-of-care ultrasound device into wide practice. The connected tool is already live at 30 of the system's "high-priority" locations, which include COVID-19 testing centers, ICUs and EDs.

“The Butterfly iQ devices have already given Atrium Health greater abilities in screening and monitoring COVID-19 patients by providing an immediate and clear picture of what’s happening in a patient’s lungs," Dr. Rasu Shrestha, EVP and chief strategy and transformation officer at Atrium, said in a statement. "But we see its benefit going well beyond the current pandemic. Our teams are already using it to provide care for heart patients, and we anticipate this device ushering in a new era of frontline care.”


Intel will be supporting the efforts of the University of Pennsylvania's Perelman School of Medicine and 29 other institutions as they seek to identify brain tumors via artificial intelligence. The effort will be employing a distributed machine learning approach called federated learning, which the partners note will allow for greater collaboration on the deep learning project without risking patients' data privacy.

“AI shows great promise for the early detection of brain tumors, but it will require more data than any single medical center holds to reach its full potential," Jason Martin, principal engineer at Intel Labs, said in a statement. "Using Intel software and hardware and support from some of Intel Labs’ brightest minds, we are working with the University of Pennsylvania and a federation of 29 collaborating medical centers to advance the identification of brain tumors while protecting sensitive patient data.”


Mobile EHR and practice management system-maker DrChrono recently unveiled a partnership with EHRsynergy that it says will help better document patient encounters. According to the announcement, the latter company's Augmented Intelligence Engine foregoes templates for machine learning-based suggestions of most likely diagnoses or treatments based on the patient's record. The physician's selections are then formatted into structured data.

“DrChrono is an important EHR partner for us because we are both committed to leveraging new technology to make medical practices more efficient and interactive,” Edward Makaron, cofounder and CEO of EHRsynergy, said in a statement.  “By syncing our information into a flexible, mobile EHR platform, we’re making it even easier for physicians to chart patient encounters on mobile devices and spend more one-on-one time with their patients.”

 

MobiHealthNews:

The latest news in digital health delivered daily to your inbox.

Thank you for subscribing!
Error! Something went wrong!